USA flag logo/image

An Official Website of the United States Government

Method to hold and release endograft for Rx of AAA

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
71006
Program Year/Program:
2004 / SBIR
Agency Tracking Number:
HL077967
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
EVA CORPORATION
EVA CORPORATION 8218 WISCONSIN AVE BETHESDA, MD 20814
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2004
Title: Method to hold and release endograft for Rx of AAA
Agency: HHS
Contract: 1R43HL077967-01
Award Amount: $100,000.00
 

Abstract:

DESCRIPTION (provided by applicant): Because of high morbidity and mortality of open repair of abdominal aortic aneurysms (AAAs), an endovascular approach to bypassing AAAs with supported (stented) endografts inserted via femoral artery sheaths has been developed. Three major complications occur with these endografts: 1) a leak can develop between the endograft and the adjacent aorta; 2) the endograft can migrate distally out of the aortic neck; and 3) the juxtaposition of fabric and metal struts can lead to complications (fraying, strut fracture). An Endostaple has been developed that will provide attachment of the endograft to the full thickness of the aortic wall. This Endostaple is currently in an FDA approved Phase I pilot study to determine safety and efficacy in treating 15 humans for proximal Type I endoleak in patients with endograft treatment of their AAA. While Endostaple treatment of leaks and prevention of migration are highly likely to be successful, supported endografts, unconstrained by adjacent arterial wall as they traverse the lumens of abdominal aneurysms, are likely to continue to have problems with strut/fabric fraying or strut fracture. Moreover, supported endografts are frequently not suitable for AAA patients whose aortic neck is wide, short, or severely angulated. Finally, the cost of each endograft exceeds $10,000. Therefore, for reasons of suspect durability, somewhat limited applicability, and high cost of supported endografts, it is important to evaluate other methods of endovascular treatment of AAAs. The goal of the proposed project is to develop a device and method of 1) inserting an unsupported bifurcation endograft through an 18 French insertion sheath, 2) opening the proximal portion of the tube portion within a simulated aortic neck, 3) holding the graft in place while Endostaples are placed circumferentially, 4) separating the holding mechanism from the endograft in a safe and reliable manner, and 5) withdrawing the holding mechanism back into the insertion sheath to facilitate safe removal. Such a device/method would, to a great extent, emulate the proven and durable approach used in the open repair technique but would incorporate the advantages of lower morbidity and mortality provided by the endovascular approach. Using such a device/method would allow more patients with AAAs to be treated effectively; it would lower the cost of endovascular repair of AAAs; and it will likely increase the long-term safety of endovascular treatment of AAAs.

Principal Investigator:

Terry J. Dahl
8055693858
TERRY.DAHL@VERIZON.NET

Business Contact:

Hugh h trout
3016521223
HTROUT3@HOTMAIL.COM
Small Business Information at Submission:

EVA CORPORATION
EVA CORPORATION 8218 WISCONSIN AVE BETHESDA, MD 20814

EIN/Tax ID: 521983365
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No